Investor FAQs

Investor FAQs

Show all

All publications are available on this Website.
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Retrophin was founded in February 2011 and became public by reverse merger in December 2012.
Retrophin’s fiscal year ends December 31.
Retrophin is traded on NASDAQ with a ticker symbol of RTRX.
Retrophin is incorporated in Delaware.
Retrophin’s CUISP number is 761299 10 6.
3721 Valley Centre Drive, Suite 200
San Diego, CA 92130
Retrophin does not pay a dividend at this time.
Retrophin does not have a Dividend Reinvestment Plan at this time.
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219 Toll free (800) 937-5449
Direct (718) 921-8124 info@amstock.com
Contact the transfer agent.
To change your address, contact the transfer agent.